The advances in applying inorganic fluorescent nanomaterials for the detection of hepatocellular carcinoma and other cancers

RSC Advances ◽  
2015 ◽  
Vol 5 (97) ◽  
pp. 79572-79584 ◽  
Author(s):  
Hetao Chen ◽  
Dongxing Shi ◽  
Yu Wang ◽  
Liwen Zhang ◽  
Qiang Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Detection ◽  
Fluorescent Nanomaterials

The advances, drawbacks and application suggestions of QDs, UCNPs and CDs in HCC and other cancer detection fields are discussed.

Ultra-sensitive diagnosis of orthotopic patient derived hepatocellular carcinoma by Fe@graphene nanoparticles in MRI

RSC Advances ◽  
2016 ◽  
Vol 6 (115) ◽  
pp. 113919-113923 ◽  
Author(s):  
Chao Zhang ◽  
Jing Ren ◽  
Yutong Yang ◽  
Dunhui Wang ◽  
Jian He ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Detection ◽  
Diagnostic Ability ◽  
Magnetic Performance ◽  
Graphene Nanoparticles ◽  
Low Cytotoxicity

mPEG-DSPE modified Fe/graphene nanoparticles showed low cytotoxicity and high magnetic performance, providing super MRI diagnostic ability for cancer detection.

SCCA1–IGM and SCCA2–IGM Compared with Total SCCA-IGM for Diagnosis of Hepatocellular Carcinoma

2009 ◽  
Vol 24 (3) ◽  
pp. 205-205
Author(s):  
Alessandra Biasiolo ◽  
Natascia Tono ◽  
Santina Quarta ◽  
Luca Beneduce ◽  
Angelo Gatta ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Cancer Detection ◽  
Immune Complexes ◽  
Primary Liver Cancer ◽  
Diagnostic Sensitivity ◽  
Serum Samples ◽  
Sensitivity Score ◽  
Commercial Assay ◽  
The Family

Introduction SCCA1 and SCCA2 belong to the family of serine protease inhibitors (SERPIN). Both SCCA isoforms have been found to be increased in patients with squamous cell carcinoma (SCC) of different organs. Recent findings have demonstrated that SCCA-IgM immune complexes are a novel class of biomarkers for primary liver cancer detection. An increase in SCCA-IgM levels in patients with cirrhosis is associated with the development of liver cancer. Aims and methods To evaluate the diagnostic accuracy of different isoforms of SCCA-IgM compared with a commercial assay for SCCA-IgM in patients with hepatocellular carcinoma (HCC). Twenty-six patients with HCC (M/F 1 9/7; mean age ± SD: 65 ± 13 years) were analyzed. Serum samples from 28 blood donors (M/F 17/11; mean age ± SD: 38 ± 9 years) were used as control. Two monoclonal antibodies, SCC 111 and SCC 1 04 (CanAg Diagnostics, Gothenburg, Sweden) were used as catcher antibodies to perform specific ELISA for SCCA1-lgM and SCCA2-lgM. SCCA-IgM immune complexes were also detected in serum by a commercial ELISA kit (Hepa-IC, Xeptagen, Marghera, Italy) according to the manufacturer's instructions. Results Circulating SCCA1-IgM was detectable in 6 out of 26 patients (sensitivity 23%), while SCCA2-lgM ELISA was positive in 9 of 26 patients (sensitivity 35%). When SCCA-IgM levels were measured using the commercial assay the diagnostic sensitivity increased to 58% (15/26). The SCCA1-IgM, SCCA2-lgM and SCCA-IgM tests had 100% specificity in healthy controls. Conclusions The commercial assay allowed the detection of both isoforms of SCCA forming the IgM immune complexes, providing a better diagnostic sensitivity score than that obtained with the SCCA1-IgM or SCCA2-lgM test.

scholarly journals Restricted Boltzmann Machines for Classification of Hepatocellular Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
James A. Koziol ◽  
Eng M. Tan ◽  
Liping Dai ◽  
Pengfei Ren ◽  
Jian-Ying Zhang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Detection ◽  
Classification Problem ◽  
Classification Problems ◽  
Operating Characteristics ◽  
Restricted Boltzmann Machines ◽  
Boltzmann Machines ◽  
Multiple Antigen ◽  
Detection And Diagnosis

Multiple antigen miniarrays can provide accurate tools for cancer detection and diagnosis. These miniarrays can be validated by examining their operating characteristics in classifying individuals as either cancer patients or normal (non-cancer) subjects. We describe the use of restricted Boltzmann machines for this classification problem, relative to diagnosis of hepatocellular carcinoma. In this setting, we find that its operating characteristics are similar to a logistic regression standard and suggest that restricted Boltzmann machines merit further consideration for classification problems.

Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma

2019 ◽  
Vol 107 (11) ◽  
pp. 2522-2535 ◽  
Author(s):  
Nischal Koirala ◽  
Dola Das ◽  
Ehsan Fayazzadeh ◽  
Sanghamitra Sen ◽  
Andrew McClain ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Delivery ◽  
Folic Acid ◽  
Cancer Detection ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle ◽  
Polymeric Drug Delivery ◽  
Polymeric Drug

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment

Hepatocellular carcinoma

1982 ◽  
Vol 118 (1) ◽  
pp. 69-70 ◽  
Author(s):  
A. J. Bennett
Keyword(s):  
Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document